Kurvelo Kit
Product Images NDC 68180-844

8 FDA label images from Lupin Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Kurvelo (NDC 68180-844). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 01

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 01
Chemical structure diagram showing the molecular formula C21H28O2, representing the active ingredient in the pharmaceutical product Kurvelo by Lupin Pharmaceuticals, Inc. The structure illustrates the arrangement of carbon, hydrogen, and oxygen atoms typical of a steroidal compound.*
FDA Label Image

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 02

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 02
Chemical structure diagram showing the molecular structure of an active ingredient with hydroxyl groups and an alkyne group, consistent with a steroidal compound. The structure includes labeled chemical groups such as OH, CH3, and a triple bond to CH.*
FDA Label Image

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 03

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 03
A bar chart showing the number of women with a blood clot per 10,000 women years (WY) categorized by Non-Pregnant Non-COC Users, COC Users, Pregnancy, and Postpartum (12 weeks only). The chart displays increasing clot incidences, with postpartum women having the highest range from 40 to 65 and non-pregnant non-COC users the lowest range from 1 to 5. Pregnancy data note references are included.*
FDA Label Image

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 04

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 04
A scatter plot titled 'Risk of Breast Cancer with Combined Oral Contraceptive Use,' showing effect estimates (OR/RR) with 95% confidence intervals from various studies. The horizontal axis ranges from -1.5 to 2, with a vertical reference line at 1. Data points represent risk estimates for ever use and current use of oral contraceptives from seven different studies conducted between 2002 and 2017.*
FDA Label Image

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 05

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 05
A vertical schematic depicting pregnancy rates per 100 women in one year based on contraception methods. The top indicates 'Fewer Pregnancies' with methods like implants, injections, intrauterine devices, and sterilization; birth control pills, skin patches, and vaginal rings with hormones; followed by condoms and diaphragms. Lower effectiveness methods like no sex during fertile days, spermicide, and withdrawal are shown below, with 'No birth control' at the bottom representing the highest pregnancy rates.*
FDA Label Image

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 06

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 06
An illustrated weekly pill tracker diagram designed for Kurvelo, showing a four-week grid with each day labeled from Sunday to Saturday. Each day has an empty circle for marking pill intake, with directional arrows guiding daily progress. The diagram includes a note indicating "Monthly Self Breast Exam" along the right side.*
FDA Label Image

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 07

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 07
Kurvelo 0.15 mg/30 mcg tablets lidding foil label for levonorgestrel and ethinyl estradiol oral contraceptive tablets. The label shows dosage strength and storage instructions, distributor Lupin Pharmaceuticals, Inc., and manufacturer Lupin Limited India. The forming foil side is a calendar-type dosing pack with days of the week and weekly rows labeled Week 2 to Week 4, including a reminder for monthly self breast exam.*
FDA Label Image

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 08

12a86fc2 F0c5 4617 Acb1 4e2bd2fd3718 08
Kurvelo 0.15 mg/30 mcg tablets packaging label by Lupin Pharmaceuticals, Inc. The carton contains 3 blisters of 28 tablets each. It lists the active ingredients levonorgestrel and ethinyl estradiol, identifies the product as prescription only, and includes distributor information for Lupin Pharmaceuticals, Inc., Baltimore, MD, USA. The label also displays two barcodes and a warning that the product does not protect against HIV or other sexually transmitted diseases.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.